Talal Andrew H, Dharia Arpan, Markatou Marianthi, Brown Lawrence S, Bossert Kenneth E, Grubbs Zakiya, Mukhopadhyay Raktim, Ntiri-Reid Boatemaa, Houtsmuller Elisabeth J
Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 875 Ellicott Street, Buffalo, NY, 14203, United States, 1 716-829-3101, 1 716-854-1397.
Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, United States.
JMIR Public Health Surveill. 2025 Jul 16;11:e68854. doi: 10.2196/68854.
People with opioid use disorder (OUD) have the highest rates of hepatitis C virus (HCV) infection. Despite the availability of curative HCV medication, people with OUD have limited health care access largely due to stigma. In a recent, pragmatic, randomized controlled trial (RCT), we compared a facilitated telemedicine intervention for HCV treatment integrated into opioid treatment programs (OTPs) with off-site referral. Facilitated telemedicine is bidirectional videoconferencing between a remote provider and a patient, supported by a case manager who facilitates the telemedicine encounter. The case manager schedules telemedicine visits, provides appointment reminders, and operates the digital equipment. Among 602 participants in the RCT, 90% (n=262) were cured through facilitated telemedicine and 39% (n=123) were cured through off-site referral. In this work, a multidisciplinary group of investigators, who directed the RCT, conducted a workshop, "Advancing Viral Hepatitis Screening and Treatment in Opioid Treatment Settings - Models & Resources," at the American Association for Treatment of Opioid Dependence Conference in May 2024 to disseminate knowledge of facilitated telemedicine, including implementation considerations. We highlighted facilitated telemedicine as a patient-centered, sociotechnical, pragmatic health care delivery model for underserved populations.
This study aimed to identify lessons learned to successfully overcome challenges of facilitated telemedicine implementation for HCV treatment integrated into OTPs.
We partnered with the National Alliance of State and Territorial AIDS Directors in planning the workshop. The workshop consisted of 7 presentations on topics related to facilitated telemedicine implementation. The workshop was recorded and transcribed by Zoom (Zoom Communications). The transcripts served as data for the thematic analysis. The transcripts were interpreted to elucidate patterns of meanings and nuances derived from each presentation. In an iterative process, preliminary findings were compared and coalesced into themes. Verbatim quotes from the workshop were highlighted to support the themes.
We developed 3 themes. First, patient-centered care promotes HCV treatment for underserved populations through facilitated telemedicine. Case managers leveraged the destigmatizing environment of the OTP to build trust with patients, promoting an HCV cure through facilitated telemedicine. Second, sociotechnical approaches expand health care access for people with OUD. To be effective, facilitated telemedicine integrates 2 necessary components, a social aspect and a technical aspect. Third, facilitated telemedicine supports pragmatic research emphasizing people with OUD. Pragmatic research of facilitated telemedicine is needed to assess sustainability and scaling considerations beyond OTPs. Overall, we found that facilitated telemedicine overcame the digital divide, promoting access to digital technology, internet provision, and digital literacy.
Facilitated telemedicine incorporates both a technical and a social component. The technical component largely addresses geographical challenges, while the social component addresses temporal (ie, care coordination) issues, promotes trust, and largely assuages patients' concerns related to HCV treatment. The patient-centered, sociotechnical intervention can address the digital divide, thereby increasing health care access.
阿片类药物使用障碍(OUD)患者的丙型肝炎病毒(HCV)感染率最高。尽管有治愈HCV的药物,但由于污名化,OUD患者获得医疗保健的机会有限。在最近一项务实的随机对照试验(RCT)中,我们将纳入阿片类药物治疗项目(OTP)的HCV治疗便利远程医疗干预与非现场转诊进行了比较。便利远程医疗是远程医疗服务提供者与患者之间的双向视频会议,由一名协助远程医疗会诊的个案管理员提供支持。个案管理员安排远程医疗就诊、提供预约提醒并操作数字设备。在该RCT的602名参与者中,90%(n = 262)通过便利远程医疗治愈,39%(n = 123)通过非现场转诊治愈。在这项工作中,指导该RCT的多学科研究团队于2024年5月在美国阿片类药物依赖治疗协会会议上举办了一次研讨会,主题为“推进阿片类药物治疗环境中的病毒性肝炎筛查和治疗——模式与资源”,以传播便利远程医疗的知识,包括实施方面的考虑因素。我们强调便利远程医疗是一种以患者为中心、社会技术、务实的医疗服务提供模式,适用于服务不足的人群。
本研究旨在确定成功克服将便利远程医疗实施于纳入OTP的HCV治疗所面临挑战的经验教训。
我们与国家州和领地艾滋病主任联盟合作规划了此次研讨会。该研讨会包括七场关于便利远程医疗实施相关主题的报告。研讨会由Zoom(Zoom通信公司)进行录制和转录。这些文字记录用作主题分析的数据。对文字记录进行解读以阐明每场报告所衍生的意义模式和细微差别。在一个迭代过程中,对初步结果进行比较并合并为主题。突出了研讨会上的逐字引用来支持这些主题。
我们确定了三个主题。首先,以患者为中心的护理通过便利远程医疗促进了服务不足人群的HCV治疗。个案管理员利用OTP消除污名化的环境与患者建立信任,通过便利远程医疗促进HCV治愈。其次,社会技术方法扩大了OUD患者获得医疗保健的机会。为了有效,便利远程医疗整合了两个必要组成部分,一个社会方面和一个技术方面。第三,便利远程医疗支持以OUD患者为重点的务实研究。需要对便利远程医疗进行务实研究,以评估OTP之外的可持续性和推广考虑因素。总体而言,我们发现便利远程医疗克服了数字鸿沟,促进了数字技术、互联网接入和数字素养的获取。
便利远程医疗包含技术和社会两个组成部分。技术部分主要解决地理挑战,而社会部分解决时间(即护理协调)问题,促进信任,并在很大程度上缓解患者对HCV治疗的担忧。这种以患者为中心的社会技术干预可以解决数字鸿沟问题,从而增加医疗保健的可及性。